These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 17571370

  • 1. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y, Komuro I, Akazawa H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
    Kageyama S.
    Nihon Yakurigaku Zasshi; 2008 Mar 28; 131(3):180-1. PubMed ID: 18421844
    [No Abstract] [Full Text] [Related]

  • 5. [AT 1-blocker can be given in addition to ACE inhibitor and beta blocker. "Triple therapy decidedly well tolerated even in severe heart failure"].
    Dietz R.
    MMW Fortschr Med; 2004 May 27; 146(22):50. PubMed ID: 15373115
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K.
    Internist (Berl); 2004 Sep 27; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract] [Full Text] [Related]

  • 9. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun 27; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 10. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Mitsuyama S.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():78-83. PubMed ID: 17571369
    [No Abstract] [Full Text] [Related]

  • 14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 15. [Hyperkalemia, heart failure and reduced renal function].
    Bugge JF.
    Tidsskr Nor Laegeforen; 2010 Jul 01; 130(13):1354-5. PubMed ID: 20596118
    [No Abstract] [Full Text] [Related]

  • 16. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 01; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 17. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep 18; 145(38):6. PubMed ID: 14603670
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.